BioSpace News Archive

Axsome Therapeutics, Inc. today announced it will report its financial results for the fourth quarter and full year of 2023 on Tuesday, Feb. 20, 2024, before the opening of the U.S. financial markets.

ONL Therapeutics, Inc. announced that David Zacks, M.D., Ph.D. and the Edna H. Perkiss will present an update on the company’s Phase 2 study in patients with rhegmatogenous retinal detachment at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 – 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.

Biomica Ltd. announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024.

Acurx Pharmaceuticals, Inc. today announced that David P. Luci , President & Chief Executive Officer, will be presenting at The Microcap Conference, which will take place January 30, 2024-February 1, 2024 at the Ceasars Atlantic City Hotel & Casino in Atlantic City, New Jersey.

Inhibrx, Inc. and Sanofi announced that the companies have entered into a definitive agreement under which Aventis Inc., a Pennsylvania corporation will acquire all the assets and liabilities associated with INBRX-101, an optimized, recombinant alpha-1 antitrypsin augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc.

Amadix, a Spanish biotech company, announced that PreveCol®, its colorectal cancer screening blood test, has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has scheduled the release of its 2023 fourth quarter and full year financial results for Monday, February 5, 2024 before the market opens.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, announced the closing of an up to $65 million senior secured credit facility with Hercules Capital, Inc., a leader in customized debt financing for companies in life sciences and technology-related markets.

AbCellera (Nasdaq: ABCL) will announce its full year 2023 financial results on Tuesday, February 20, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.